drugset
drugset / Trial / NCT05584306

A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

NCT05584306 ↗

Phase 1 Unknown 24 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Timeline

Start
2021-12-06
Primary completion
2023-09
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 610 Monoclonal antibody 30 mg Subcutaneous
Subject 610 Monoclonal antibody 100 mg Subcutaneous
Subject 610 Monoclonal antibody 300 mg Subcutaneous

Indications

asthma